JILIN AODONG(000623)2023-12-07 09:32Group 1: Company Overview - Jilin Aodong Pharmaceutical Group Co., Ltd. has a history dating back to 1957, evolving from a state-owned enterprise to a publicly listed company in 1996 [6] - The company operates 22 subsidiaries, including 6 specialized pharmaceutical companies, 1 R&D subsidiary, and 5 sales subsidiaries [7] Group 2: Financial Performance - For the first three quarters of 2023, the company achieved a revenue of CNY 2.354 billion, a year-on-year increase of 23.05% [2] - The sales revenue of Shenxin Bn Brain Liquid reached CNY 539 million, up 25.48% year-on-year [4] - The company’s other core products, such as Pediatric Chai Gui Fever Oral Liquid and Xuefu Zhuyu Oral Liquid, also showed significant growth, with sales of CNY 142 million (49.17% increase) and CNY 65.26 million (15.24% increase) respectively [4] Group 3: Product Development - The company focuses on three core traditional Chinese medicine products: Shenxin Bn Brain Liquid, Pediatric Chai Gui Fever Oral Liquid, and Xuefu Zhuyu Oral Liquid, all of which have seen steady sales growth [4] - The company has completed the registration of 368 varieties of traditional Chinese medicine formula granules, ensuring a robust market presence [6] Group 4: Investment Strategy - Jilin Aodong holds a 19.72% stake in Guangfa Securities, which is considered a core quality asset for the company [4] - The company plans to invest CNY 442 million in the traditional Chinese medicine formula granule project, with an expected total investment of CNY 1.002 billion [6] Group 5: Future Outlook - The company aims to enhance its product offerings and market competitiveness through continuous R&D and strategic investments [6] - The projected annual sales revenue from the traditional Chinese medicine formula granule project is CNY 1.263 billion, with an average annual profit of CNY 234.92 million [6]